Ignite Creation Date:
2025-12-24 @ 7:46 PM
Ignite Modification Date:
2026-02-07 @ 12:57 PM
Study NCT ID:
NCT05281003
Status:
RECRUITING
Last Update Posted:
2023-07-13
First Post:
2022-03-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
Sponsor:
Fudan University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Esophageal Squamous Cell Carcinoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Programmed Cell Death-1 (PD1, PD-1) | View |
| None | Programmed Cell Death Receptor Ligand 1 (PDL1, PD-L1) | View |
| None | Esophageal Neoplasms | View |
| None | Neoplasms | View |
| None | Gastrointestinal Neoplasms | View |
| None | Digestive System Neoplasms | View |
| None | Pembrolizumab | View |
| None | Antineoplastic Agents | View |
| None | Antineoplastic Agents, Immunological | View |
| None | Immune Checkpoint Inhibitors | View |
| None | Neoadjuvant Therapy | View |
| None | Drug Resistance, Neoplasm | View |
| None | Hypoxia | View |